| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Experimental Therapeutics |
Department of Human Oncology, University of Wisconsin School of Medicine and Comprehensive Cancer Center, Madison, Wisconsin 53792
 |
ABSTRACT |
|---|
 Top ABSTRACT INTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
|
INTRODUCTION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
750,000 new cases diagnosed annually. Radiation therapy plays a primary role in treatment for patients with SCC of the H&N. However, the rapid proliferation of surviving tumor clonogens during and after radiotherapy serves to compromise ultimate tumor control (1)
. Biological approaches that use growth factor inhibitors to modify tumor proliferation and/or radiosensitivity offer potential for improving tumor control. The EGFR represents a promising therapeutic target in epithelial tumors. The EGFR serves as an important regulator of cellular proliferation but also contributes to other processes that are central to cancer progression, including angiogenesis and metastatic spread (2)
. EGFR is overexpressed by a variety of human tumors, particularly SCC of the H&N. Several studies demonstrate a positive correlation between EGFR expression and cellular resistance to radiation (3, 4, 5, 6)
. SCC cells derived from H&N cancer patients that express high levels of EGFR appear to be more radioresistant than those expressing low levels of EGFR (4)
. The degree of radioresistance correlates positively with the magnitude of EGFR overexpression (5)
. Additional studies suggest that cell survival and repopulation during a course of radiotherapy are influenced, in part, by activation of EGFR/TGF-
that is induced after exposure to radiation (7)
. These results suggest that modulation of EGFR signaling represents a promising strategy for improving tumor control with radiation (8)
. ZD1839 ("Iressa") is an EGFR-selective tyrosine kinase inhibitor that blocks signal transduction pathways implicated in cancer cell proliferation, survival, and other host-dependent processes promoting cancer progression (9) . ZD1839 inhibits EGFR in vitro with an IC50 of 23 nM (10) and demonstrates much lesser activity against HER2 (IC50 of 2 µM). ZD1839 possesses good oral bioavailability and demonstrates antitumor activity across a broad range of mouse models. A series of studies have evaluated the combined antiproliferative effect of treatment with ZD1839 and a variety of cytotoxic drugs with different mechanisms of action (11) . A supra-additive growth-inhibitory effect was observed with ZD1839 and several cytotoxic drugs tested in vitro and in human xenograft tumor models. Phase I clinical trials with ZD1839 as monotherapy confirm that treatment is generally well tolerated and provide evidence of antitumor activity (12) . These successes have led to additional clinical investigations regarding the effects of ZD1839 in combination with conventional cytotoxic drugs or radiation.
There are a series of recently published abstracts that describe the capacity of ZD1839 to modulate radiation response in human tumor cell lines and xenografts (13, 14, 15, 16, 17, 18, 19) . The present study represents the first full publication to examine potential therapeutic advantage of combining ZD1839 with radiation in a series of in vitro and in vivo experimental systems. Our results confirm that treatment with ZD1839 reduces clonogenic survival of SCC cells after exposure to radiation. Moreover, coadministration of ZD1839 with focal radiation enhances the antitumor potency of radiation against human SCC xenografts in athymic mice. In addition, we offer experimental evidence suggesting that potentiation of the antitumor activity of ionizing radiation by ZD1839 is mediated in part by effects on cellular apoptosis and tumor angiogenesis.
|
MATERIALS AND METHODS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Cell Lines and Cell Culture.
Human SCC cell lines were established from biopsies of H&N cancer patients. The SCC-13Y cell line was derived from the facial epidermis and was provided by Dr. B. Lynn Allen-Hoffmann (University of Wisconsin-Madison). The SCC-1 cell line (floor of mouth) and SCC-6 cell line (tongue) were provided by Dr. Thomas E. Carey (University of Michigan). SCC cells were cultured routinely in DMEM supplemented with 5% fetal bovine serum, 1 µg/ml hydrocortisone, and 1% penicillin and streptomycin. HUVECs were kindly provided by Dr. Deane F. Mosher (University of Wisconsin-Madison) and cultured in MCDB 131-complete medium purchased from VEC Technologies, Inc. (Rensselaer, NY).
Growth Inhibition Assay.
The antiproliferative effect of ZD1839 on human SCC cell lines was evaluated using MTT assay as described previously (20)
. Briefly, exponentially growing SCC cells were seeded into 96-well plates and incubated in medium containing ZD1839 from 0 to 100 µM for 24 h at 37°C. Duplicate plates containing six replicate wells/assay condition were seeded at a density of 1500 cells in 0.1 ml of medium. ZD1839 was solubilized in DMSO. Final concentration of DMSO in all cultures, including controls, was 0.1%. After exposure of cells to ZD1839, 100 µl of MTT (1 mg/ml) were added to each well for 2 h at 37°C to allow MTT to form formazan crystals by reacting with metabolically active cells. The formazan crystals were solubilized overnight at 37°C in a solution containing 10% of SDS and 50% of N,N-dimethylformamide. The absorbance of each well was measured in a microplate reader at 600 nm. The percentage cell growth was calculated by comparison of the A600 reading from treated versus control cells.
Flow Cytometric Analysis of Cell Cycle.
Control or ZD1839-treated cells were harvested by trypsinization, washed with PBS, then fixed in 95% ethanol, and stored at 4°C for up to 7 days before DNA analysis. After the removal of ethanol by centrifugation, cells were then incubated with phosphate-citric acid buffer [0.2 M Na2HPO4 (pH 7.8), and 4 mM citric acid] at room temperature for 45 min. After centrifugation, cells were then stained with a solution containing 33 µg/ml PI, 0.13 mg/ml RNase A, 10 mM EDTA, and 0.5% Triton X-100 at 4°C for 24 h. Stained nuclei were analyzed for DNA-PI fluorescence using a Becton Dickinson FACScan flow cytometer. Resulting DNA distributions were analyzed by Modfit (Verity Software House, Inc., Topsham, ME) for the proportion of cells in sub-G0, G1, S, and G2-M phases of the cell cycle.
Flow Cytometric Quantitation of Apoptosis.
Apoptosis was detected by examination of altered plasma membrane phospholipid packing, which was quantitated by the incorporation of the lipophilic dye MC540 and Ho342 dye (21)
. The validity of MC540 staining as a measure of entry into apoptosis has been established in previous experimental systems in which cell morphology, changes in light scatter parameter, and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling DNA end-labeling were evaluated in parallel experiments (21
, 22) . Ho342 is a DNA-specific dye that allows for the analysis of cell cycle position. Specifically, cells were harvested with 5 mM EDTA at 37°C. After centrifugation, cell pellets were resuspended in 900 µl of PBS, followed by the addition of 100 µl of 50 µg/ml Ho342. Thereafter, cells were incubated for 30 min in the dark, pelleted, and resuspended in 100 µl of PBS. Four µl of MC540 (1 mg/ml) were added, and cells were incubated for 20 min in the dark. Cells were pelleted, resuspended in 1 ml PBS, and analyzed immediately by flow cytometry. MC540-positive cells were marked by an increase in red fluorescence, collected at 575 ± 20 nm, 0.5–2 log over MC540-negative cells. Data were collected and analyzed using CellQuest software (Becton Dickinson). MC540 bright cells in different cell cycle positions were classified as apoptotic.
Radiation Survival.
Survival after radiation exposure was defined as the ability of the cells to maintain their clonogenic capacity and to form colonies. Briefly, after exposure to radiation, cells were trypsinized, counted, and seeded for colony formation in 35-mm dishes at 50–5000 cells/dish. After incubation intervals of 14–21 days, colonies were stained with crystal violet and manually counted. Colonies consisting of 50 cells or more were scored, and 4–10 replicate dishes containing 10–150 colonies/dish were counted for each treatment.
Assay of Tumor Growth in Athymic Nude Mice.
Athymic nude mice (3–4-week-old females) were obtained from Harlan Bioproducts for Science (Indianapolis, IN) and maintained in a laminar air-flow cabinet under aseptic conditions. The care and treatment of experimental animals was in accordance with institutional guidelines. Human SCC cells (1 x 106) were injected s.c. into the right (SCC-6) and left (SCC-1) flank area of the mice on day 0. Tumor volume was determined by direct measurement with calipers and calculated by the formula 
/6 x (large diameter) x (small diameter)2. Animal experiments generally included four treatment groups: control, radiation alone, ZD1839 alone, and radiation in combination with ZD1839. ZD1839 was administered by oral gavage at the specified doses and intervals. Radiation treatment was delivered via precision electron beam from a Varian linear accelerator using custom-designed mouse jigs. These jigs immobilized the animals and specifically exposed the dorsal flank (harboring tumor xenografts) for irradiation without exposing non-tumor-bearing normal tissues.
In Vitro Angiogenesis Assay (Capillary-like Network Formation).
For reconstitution of a basement membrane, Matrigel was diluted 2-fold with cold DMEM and added to the 24-well tissue culture plate (250 µl/well) at 4°C. The 24-well plate was brought to a 37°C cell culture incubator and incubated for 1 h to allow the Matrigel to solidify. HUVECs were trypsinized, counted, resuspended in MCDB-131, and added on top of the reconstructed basement membrane (1000 cells/ml/well) in the absence or presence of ZD1839 (1 µM). Cells were incubated for the indicated time intervals to allow capillary-like structure formation. For ease of handling and optimal visualization of endotubes, medium was removed after incubation, and agarose (250 µl/well, 0.5% in PBS, 50°C) was gently added drop-by-drop to the cells. After solidification of agarose (2–5 min at room temperature), immobilized endotubes were fixed with formalin (200 µl/well; 30 min) and washed twice with 250 µl of PBS. The endotubes were then stained with Diff-Quik solution for 20 min, followed by extended washing with water (6 x 1 ml/well over at least 24 h). The numbers of endotubes were subsequently quantified by counting nine random fields/sample under the microscope.
Tumor Xenograft Angiogenesis Assay (Matrigel Plug).
The Matrigel plug neovasculation assay was developed by Drs. Nasim Akhtar and Robert Auerbach (University of Wisconsin-Madison) (23)
. Athymic mice were injected s.c. along the abdominal midline with 0.5 ml Matrigel. After 24 h, a suspension of SCC-1 cells (5 x 105 in 5 µl) was soaked with a polyvinyl sponge (1 x 1 x 0.5 mm). The sponge was then introduced into a surgically created micropocket in the center of Matrigel plug formed within the mouse abdominal wall. After 24 h, mice began receiving 0.8 mg of ZD1839 p.o. once per day for 10 consecutive days. Thereafter, mice received injections of 0.2 ml of a 50 mg/ml FITC-Dextran (Mr 2,000,000) solution via the tail vein for the purpose of visualizing vessels within the Matrigel plug. After 20 min, mice were sacrificed, and the Matrigel plugs were removed and fixed in 10% formalin solution. To visualize the general layout of the Matrigel plug and the presence of perfused blood vessels, phase-contrast microscopy and fluorescence microscopy were used, respectively. The intensity of fluorescence was further quantified by Adobe Photoshop software (Adobe Systems, Mountain View, CA).
Statistical Analysis.
The effects of radiation and/or ZD1839 on growth inhibition, radiation survival, and apoptosis were assessed by multiple regression analysis using the PROC general linear model procedure in SAS (version 8; SAS Institute, Inc., Cary, NC). In experiments involving multiple radiation doses or ZD1839, the linear quadratic model with the following equation was used: log(surviving fraction) = -D - ßD2, where D represents the dose of radiation (Gy) or dose of ZD1839 (µM). For xenograft studies, data on tumor volume were transformed into ranks and analyzed by nonparametric procedures.
|
RESULTS |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
, ZD1839 treatment inhibited cellular proliferation in a dose-dependent manner in all SCC cell lines tested. All three SCC cell lines showed significant growth inhibition with ZD1839 at a concentration of 
10 µM. SCC-13Y was somewhat more sensitive to ZD1839 than SCC-1 and SCC-6, particularly at the highest concentration of ZD1839 (100 µM). This trend was supported by a significant interaction between the cell line and the growth-inhibitory effect of ZD1839 (P < 0.001) in regression analysis. Because SCC-13Y shows the lowest EGFR expression among these three SCC cell lines tested (data not shown), our results suggest that EGFR expression level alone is likely not the sole determinant influencing the antiproliferative activity of ZD1839.
|
. Treatment with 1 µM ZD1839 for 48 h induced accumulation of cells in G1 phase with a significant decrease in the percentage of cells in S-phase relative to controls. No significant changes in the percentage of cells within G2-M phase were observed in these experiments. The ZD1839-induced G1 arrest was further confirmed by examining the effect of ZD1839 on the expression of several key regulators of the G1-S-phase transition. Western blot analysis confirmed that treatment with ZD1839 increased expression of the cyclin-dependent kinase inhibitor p27, hypophosphorylated retinoblastoma protein, and decreased expression of cyclin D1 and E (data not shown).
|
depicts radiation survival curves for SCC-1 and SCC-6 cells exposed to ZD1839 before radiation. Our results demonstrate that treatment with ZD1839 before radiation significantly reduced cell survival compared with control (P < 0.01) in both cell lines. When the data were analyzed according to the linear quadratic model in SCC-1 cells, the :ß ratios are 0.95 and 4.34 for the control and the ZD1839 groups, respectively. These data indicate that treatment with ZD1839 results in a steeper decline in cell survival with a higher :ß ratio and enhancement of radiosensitivity with the higher coefficient. Similar results were observed in SCC-6 cells (control curve: /ß = 17.02; ZD1839-treated curve: /ß = 23.03).
|
. In contrast, combined treatment with radiation and ZD1839 significantly inhibited tumor growth and resulted in substantial growth delay in both SCC-1 and SCC-6 xenografts. For SCC-6 xenografts, statistical analysis indicated that combined treatment with radiation and ZD1839 was associated with an additive effect on tumor growth inhibition. The combined treatment with radiation and ZD1839 produced a synergistic tumor growth inhibition in SCC-1 xenografts beyond day 51 (P < 0.01). This synergistic interaction between ZD1839 and radiation increased over time, as indicated by diminishing Ps from day 51 (P = 0.009) to day 68 (P = 0.008) and finally to day 75 (P = 0.005).
|
, radiation alone (6 Gy) or ZD1839 alone induced early apoptosis to a similar degree (approximately 4–8%) compared with control. However, combined treatment with radiation and ZD1839 resulted in substantially more potent induction of apoptosis (increased by 23% compared with control), which was greater than additive with P < 0.001. The enhancement of radiation-induced apoptosis by ZD1839 was further confirmed by a distinct assay approach (flow cytometry) using PI labeling of the DNA. This method examines the appearance of hypodiploid nuclei (sub-G0), which reflects the terminal stage of apoptosis. This approach also confirmed a potentiation of radiation-induced apoptosis in SCC cells by ZD1839 (data not shown).
|
. At 18 h, the inhibitory effect of ZD1839 was clearly noted. Conversely, the endotubes formed by control cells continued to differentiate and mature. As the incubation period lengthened, cells treated with ZD1839 gradually lost their cell-to-cell connections. This destabilizing effect became very obvious by 30 h, when the capillary-like network of HUVECs displayed substantial fragmentation and dissociation, resulting in the loss of most intercellular contacts. The number of endotubes was substantially reduced at 18 and 30 h (>60 and >75%, respectively) in the ZD1839-treated group (Fig. 6B)
.
|
. The control plugs containing SCC-1 cells showed extensive vascularization and growth of vessels toward the tumor core within 10 days. In contrast, plugs in those mice treated with ZD1839 showed markedly reduced vascularization (Fig. 7A)
, which was confirmed by the reduced intensity of fluorescence relative to untreated groups (Fig. 7B)
. These results suggest that ZD1839 can inhibit tumor-induced angiogenesis.
|
|
DISCUSSION |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Findings from our human xenograft studies demonstrate that ZD1839 treatment is associated with an additive (SCC-6) or synergistic (SCC-1) effect on tumor growth inhibition when combined with ionizing radiation. The success of radiation therapy to effect local tumor control is influenced by multiple factors including overall clonogenic burden, intrinsic radiosensitivity, oxygenation status, and cellular repopulation capacity and repair. It has been reported previously that SCC-1 and SCC-6 exhibit distinct radiosensitivities (SCC-6, radiosensitive; SCC-1, radioresistant; Ref. 25
). Our current observation that radiation alone inhibited the growth of the SCC-6 tumor xenografts more significantly than for the SCC-1 tumor xenografts (Fig. 4)
is consistent with these known radiosensitivity profiles. Therefore, differential effects observed with combined radiation and ZD1839 on tumor growth between SCC-1 and SCC-6 may be partially attributable to differences in their intrinsic radiosensitivity.
Inhibition of tumor angiogenesis may also contribute to the antitumor potency of ZD1839 plus radiation observed within the xenograft model systems because a mechanistic linkage between EGFR signaling and angiogenesis has been identified recently (26
, 27)
. TGF- can induce transcriptional activation of the angiogenic factor, VEGF (26)
. Blockade of EGFR results in reduced expression of VEGF mRNA and protein, as well as interleukin 8 and basic fibroblast growth factor in tumor cells (27)
. Using the Matrigel plug neovascularization assay, we demonstrate that treatment of mice with ZD1839 significantly reduces vessel formation and inhibits the propensity of vessels to grow toward the central core of SCC-1 tumor implantation. We further demonstrate that ZD1839 inhibits the early angiogenic process by targeting endothelial cells, i.e., by decreasing cell-to-cell interaction and disrupting endotube formation (Fig. 6)
.
Endothelial cells from several neoplasms have been shown to express EGFR (28)
. Binding of TGF- to EGFR on endothelial cells stimulates their proliferation (29)
. Conversely, blockade of the EGFR leads to apoptosis of endothelial cells and to a subsequent reduction in neovascularity (30)
. The respective roles of endothelial cells and tumor cells in the overall tissue response to radiotherapy remain controversial. Paris et al. (31)
provide recent evidence that endothelial cells may represent principal targets for radiation, whereas tumor cell death may represent a secondary event after demise of endothelial cells on which tumor cells ultimately depend. The effect of ZD1839 on endothelial cells observed in our studies warrants further investigation regarding the capacity of ZD1839 to modify the radiation response profile of endothelial cells.
Cellular apoptosis represents another process that may influence the ultimate response of a particular tumor to ionizing radiation (32 , 33) . In a study comparing two murine tumors, one radiosensitive (ovarian carcinoma) and one radioresistant (hepatocellular carcinoma), the former was found to be much more susceptible to induction of apoptosis by radiation. A similar correlation was observed between the amount of apoptosis and the degree of radiosensitivity in two mouse lymphoma cell lines (34) . These data suggest that apoptotic propensity may influence intrinsic tumor cell radiosensitivity. Recent studies in human SCCs (35) and colorectal carcinomas (36) indicate that EGFR signaling blockade (with the anti-EGFR monoclonal antibody C225) can itself induce apoptosis. The colorectal work further suggests that subcellular redistribution of Bax protein may influence this response. In the present study with SCCs, we demonstrate that molecular inhibition of EGFR tyrosine kinase with ZD1839 exerts a modest independent effect on apoptosis but effects a clear enhancement of radiation-induced apoptosis. It suggests that treatment with ZD1839 not only enhances cell death after radiation but also increases the fraction of tumor cells succumbing to radiation-induced apoptosis.
ZD1839 inhibits cellular proliferation across a variety of SCC cell lines with various EGFR levels. Interestingly, the degree of proliferative inhibition may not correlate with the level of EGFR expression, as indicated by results in Fig. 1
. Other studies report quite similar observations. A recent study suggests that the sensitivity of tumor cells to ZD1839 is not correlated with EGFR expression but rather with HER2 expression (37)
. In a panel of 10 human breast cancer and other epithelial tumor cell lines, Moasser et al. (37)
found that HER2-overexpressing tumors were more sensitive to ZD1839 than others, with IC50s <10 µM. The highest sensitivity was observed among those tumors with the greatest HER2 expression, with IC50s <1 µM. No apparent correlation between the expression level of EGFR and tumor sensitivity to ZD1839 was identified in this study. In a study by Sirotnak et al. (38)
, tumor cell lines with various EGFR expression levels were used to examine the influence of EGFR expression on the cytotoxic effect of chemotherapy agents combined with ZD1839. The EGFR expression level did not substantially influence the cytotoxic antitumor activity by ZD1839 or the activity of ZD1839 alone. These results suggest that ZD1839 influences tumor response through inhibition of EGFR, HER2, and perhaps both. HER2 functions preferentially as a heterodimer with other HER family members including EGFR. ZD1839 may therefore also represent a valuable agent in the treatment of patients with HER2-overexpressing tumors, such as selected breast cancers (39
, 40)
. Indeed, the clinical testing of ZD1839 need not necessarily be confined to patients with EGFR-overexpressing tumors.
In conclusion, ZD1839 offers promise in the treatment of epithelial tumors that rely on ErbB signaling for their growth advantage. The studies presented in this report indicate that human epithelial cancer cells (SCCs) are particularly sensitive to radiation when EGFR signaling is inhibited by ZD1839. This finding expands upon recent results with other EGFR inhibitory agents (i.e., C225), which act via blockade of the extracellular receptor domain to inhibit EGFR signaling (35 , 41 , 42) . The fact that epithelial tumors comprise approximately two-thirds of human tumors, with many relying on EGFR signaling for cellular growth and differentiation, suggests a broad applicability of this molecular target in human cancer therapy. Clinical trials are now in progress to examine the impact of ZD1839 (and other EGFR-inhibitory agents) on radiation response and patient survival in a spectrum of human malignancies.
|
ACKNOWLEDGMENTS |
|---|
|
FOOTNOTES |
|---|
1 Iressa is a trademark of the AstraZeneca group of companies. 
2 To whom requests for reprints should be addressed, at Department of Human Oncology, University of Wisconsin Comprehensive Cancer Center, 600 Highland Avenue, Madison, WI 53792-0600. Phone: (608) 263-5342; Fax: (608) 263-9947; E-mail: harari{at}mail.humonc.wisc.edu
3 The abbreviations used are: SCC, squamous cell carcinoma; H&N, head and neck; EGFR, epidermal growth factor receptor; TGF, transforming growth factor; MTT; 3-(4,5-dimethylthiazol-1,2-yl)-2,5-diphenyl tetrazolium bromide; PI, propidium iodide; Ho342, Hoechst 33342; MC540, merocyanine 540; HUVEC, human umbilical vascular endothelial cell; VEGF, vascular endothelial growth factor.
Received 1/21/02. Accepted 6/ 5/02.
|
REFERENCES |
|---|
|
TopABSTRACTINTRODUCTIONMATERIALS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
-induced transcriptional activation of the vascular permeability factor (VPF/VEGF) gene requires AP-2-dependent DNA binding and transactivation. EMBO J., 16: 750-759, 1997.[Medline]
This article has been cited by other articles:
|
|
 |
|
  S. YABUUCHI, Y. KATAYOSE, A. ODA, M. MIZUMA, S. SHIRASOU, T. SASAKI, K. YAMAMOTO, M. OIKAWA, T. RIKIYAMA, T. ONOGAWA, et al. ZD1839 (IRESSA(R)) Stabilizes p27Kip1 and Enhances Radiosensitivity in Cholangiocarcinoma Cell Lines Anticancer Res, April 1, 2009; 29(4): 1169 - 1180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Benavente, S. Huang, E. A. Armstrong, A. Chi, K.-T. Hsu, D. L. Wheeler, and P. M. Harari Establishment and Characterization of a Model of Acquired Resistance to Epidermal Growth Factor Receptor Targeting Agents in Human Cancer Cells Clin. Cancer Res., March 1, 2009; 15(5): 1585 - 1592. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ren, B. Korchin, Q.-S. Zhu, C. Wei, A. Dicker, J. Heymach, A. Lazar, R. E. Pollock, and D. Lev Epidermal Growth Factor Receptor Blockade in Combination with Conventional Chemotherapy Inhibits Soft Tissue Sarcoma Cell Growth In vitro and In vivo Clin. Cancer Res., May 1, 2008; 14(9): 2785 - 2795. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, A. Munshi, C. Brooks, J. Liu, M. L. Hobbs, and R. E. Meyn Gefitinib Radiosensitizes Non-Small Cell Lung Cancer Cells by Suppressing Cellular DNA Repair Capacity Clin. Cancer Res., February 15, 2008; 14(4): 1266 - 1273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C.-H. Gow, C.-R. Chien, Y.-L. Chang, Y.-H. Chiu, S.-H. Kuo, J.-Y. Shih, Y.-C. Chang, C.-J. Yu, C.-H. Yang, and P.-C. Yang Radiotherapy in Lung Adenocarcinoma with Brain Metastases: Effects of Activating Epidermal Growth Factor Receptor Mutations on Clinical Response Clin. Cancer Res., January 1, 2008; 14(1): 162 - 168. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Mitra In Reply J. Clin. Oncol., October 10, 2007; 25(29): 4698 - 4699. [Full Text] [PDF]
|
|
|
|
|
|
P. M. Harari, G. W. Allen, and J. A. Bonner Biology of Interactions: Antiepidermal Growth Factor Receptor Agents J. Clin. Oncol., September 10, 2007; 25(26): 4057 - 4065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Erjala, M. Sundvall, T. T. Junttila, N. Zhang, M. Savisalo, P. Mali, J. Kulmala, J. Pulkkinen, R. Grenman, and K. Elenius Signaling via ErbB2 and ErbB3 Associates with Resistance and Epidermal Growth Factor Receptor (EGFR) Amplification with Sensitivity to EGFR Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cells. Clin. Cancer Res., July 1, 2006; 12(13): 4103 - 4111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. S. Mitra and R. Simcock Erlotinib Induced Skin Rash Spares Skin in Previous Radiotherapy Field J. Clin. Oncol., June 1, 2006; 24(16): e28 - e29. [Full Text] [PDF]
|
|
|
|
 |
|
 N. Pore, Z. Jiang, A. Gupta, G. Cerniglia, G. D. Kao, and A. Maity EGFR Tyrosine Kinase Inhibitors Decrease VEGF Expression by Both Hypoxia-Inducible Factor (HIF)-1-Independent and HIF-1-Dependent Mechanisms. Cancer Res., March 15, 2006; 66(6): 3197 - 3204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. J. Friedmann, M. Caplin, B. Savic, T. Shah, C. J. Lord, A. Ashworth, J. A. Hartley, and D. Hochhauser Interaction of the epidermal growth factor receptor and the DNA-dependent protein kinase pathway following gefitinib treatment. Mol. Cancer Ther., February 1, 2006; 5(2): 209 - 218. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. T. Lee, A. J. Mountain, M. P. Kelly, C. Hall, A. Rigopoulos, T. G. Johns, F. E. Smyth, M. W. Brechbiel, E. C. Nice, A. W. Burgess, et al. Enhanced Efficacy of Radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by Inhibition of Epidermal Growth Factor Receptor (EGFR) Signaling with EGFR Tyrosine Kinase Inhibitor AG1478 Clin. Cancer Res., October 1, 2005; 11(19): 7080s - 7086s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. J. Langer and M. P. Mehta Current Management of Brain Metastases, With a Focus on Systemic Options J. Clin. Oncol., September 1, 2005; 23(25): 6207 - 6219. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I.-A. Kim, S.-S. Bae, A. Fernandes, J. Wu, R. J. Muschel, W. G. McKenna, M. J. Birnbaum, and E. J. Bernhard Selective Inhibition of Ras, Phosphoinositide 3 Kinase, and Akt Isoforms Increases the Radiosensitivity of Human Carcinoma Cell Lines Cancer Res., September 1, 2005; 65(17): 7902 - 7910. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Solomon, D. Binns, P. Roselt, L. I. Weibe, G. A. McArthur, C. Cullinane, and R. J. Hicks Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging Mol. Cancer Ther., September 1, 2005; 4(9): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Bentzen, B. M. Atasoy, F. M. Daley, S. Dische, P. I. Richman, M. I. Saunders, K. R. Trott, and G. D. Wilson Epidermal Growth Factor Receptor Expression in Pretreatment Biopsies From Head and Neck Squamous Cell Carcinoma As a Predictive Factor for a Benefit From Accelerated Radiation Therapy in a Randomized Controlled Trial J. Clin. Oncol., August 20, 2005; 23(24): 5560 - 5567. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Chinnaiyan, S. Huang, G. Vallabhaneni, E. Armstrong, S. Varambally, S. A. Tomlins, A. M. Chinnaiyan, and P. M. Harari Mechanisms of Enhanced Radiation Response following Epidermal Growth Factor Receptor Signaling Inhibition by Erlotinib (Tarceva) Cancer Res., April 15, 2005; 65(8): 3328 - 3335. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. D. Chung and W. C. Broaddus Molecular Targeting in Radiotherapy: Epidermal Growth Factor Receptor Mol. Interv., February 1, 2005; 5(1): 15 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. J. Williams, B. A. Telfer, S. Brave, J. Kendrew, L. Whittaker, I. J. Stratford, and S. R. Wedge ZD6474, a Potent Inhibitor of Vascular Endothelial Growth Factor Signaling, Combined With Radiotherapy: Schedule-Dependent Enhancement of Antitumor Activity Clin. Cancer Res., December 15, 2004; 10(24): 8587 - 8593. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. McCarty, J. Wey, O. Stoeltzing, W. Liu, F. Fan, C. Bucana, P. F. Mansfield, A. J. Ryan, and L. M. Ellis ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor with additional activity against epidermal growth factor receptor tyrosine kinase, inhibits orthotopic growth and angiogenesis of gastric cancer Mol. Cancer Ther., September 1, 2004; 3(9): 1041 - 1048. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Raben, C. Bianco, V. Damiano, R. Bianco, D. Melisi, C. Mignogna, F. P. D'Armiento, L. Cionini, A. R. Bianco, G. Tortora, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xenograft model Mol. Cancer Ther., August 1, 2004; 3(8): 977 - 983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Dominguez-Escrig, J. D. Kelly, D. E. Neal, S. M. King, and B. R. Davies Evaluation of the Therapeutic Potential of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Preclinical Models of Bladder Cancer Clin. Cancer Res., July 15, 2004; 10(14): 4874 - 4884. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Castillo, M. C. Etienne-Grimaldi, J. L. Fischel, P. Formento, N. Magne, and G. Milano Pharmacological background of EGFR targeting Ann. Onc., July 1, 2004; 15(7): 1007 - 1012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Haringhuizen, H. van Tinteren, H. F. R. Vaessen, P. Baas, and N. van Zandwijk Gefitinib as a last treatment option for non-small-cell lung cancer: durable disease control in a subset of patients Ann. Onc., May 1, 2004; 15(5): 786 - 792. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M. Harari and S.-M. Huang Searching for Reliable Epidermal Growth Factor Receptor Response Predictors: Commentary re M. K. Nyati et al., Radiosensitization by Pan-ErbB Inhibitor CI-1033 in Vitro and in Vivo. Clin. Cancer Res., 10: 691-700, 2004. Clin. Cancer Res., January 15, 2004; 10(2): 428 - 432. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Janmaat and G. Giaccone Small-Molecule Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Oncologist, December 1, 2003; 8(6): 576 - 586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Li, C.-M. Chang, M. Yuan, W. G. McKenna, and H.-K. G. Shu Resistance to Small Molecule Inhibitors of Epidermal Growth Factor Receptor in Malignant Gliomas Cancer Res., November 1, 2003; 63(21): 7443 - 7450. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Liang, Y. Lu, W. Jin, K. K. Ang, L. Milas, and Z. Fan Sensitization of breast cancer cells to radiation by trastuzumab Mol. Cancer Ther., November 1, 2003; 2(11): 1113 - 1120. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-T. Le and A. J. Giaccia Therapeutic Exploitation of the Physiological and Molecular Genetic Alterations in Head and Neck Cancer Clin. Cancer Res., October 1, 2003; 9(12): 4287 - 4295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. J. Tofilon, S. Saxman, and C. N. Coleman Molecular Targets for Radiation Therapy: Bringing Preclinical Data into Clinical Trials Clin. Cancer Res., September 1, 2003; 9(10): 3518 - 3520. [Full Text] [PDF]
|
|
|
|
|
|
Y. She, F. Lee, J. Chen, A. Haimovitz-Friedman, V. A. Miller, V. R. Rusch, M. G. Kris, and F. M. Sirotnak The Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor ZD1839 Selectively Potentiates Radiation Response of Human Tumors in Nude Mice, with a Marked Improvement in Therapeutic Index Clin. Cancer Res., September 1, 2003; 9(10): 3773 - 3778. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. L. Janmaat, F. A. E. Kruyt, J. A. Rodriguez, and G. Giaccone Response to Epidermal Growth Factor Receptor Inhibitors in Non-Small Cell Lung Cancer Cells: Limited Antiproliferative Effects and Absence of Apoptosis Associated with Persistent Activity of Extracellular Signal-regulated Kinase or Akt Kinase Pathways Clin. Cancer Res., June 1, 2003; 9(6): 2316 - 2326. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Sonveaux, A. Brouet, X. Havaux, V. Gregoire, C. Dessy, J.-L. Balligand, and O. Feron Irradiation-induced Angiogenesis through the Up-Regulation of the Nitric Oxide Pathway: Implications for Tumor Radiotherapy Cancer Res., March 1, 2003; 63(5): 1012 - 1019. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Mendelsohn Targeting the Epidermal Growth Factor Receptor for Cancer Therapy J. Clin. Oncol., September 15, 2002; 20(90001): 1s - 13. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
